Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2004

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

anti-thymocyte globulin

anti-thymocyte globulin IV over 4 hours on days -2 to -1

DRUG

cyclophosphamide

cyclophosphamide IV over 1 hour on days -3 to -2

DRUG

cyclosporine

oral cyclosporine on days -1 to 100

DRUG

fludarabine phosphate

fludarabine IV over 30 minutes on days -8 to -4

DRUG

methylprednisolone

methylprednisolone (oral or IV) on days 5-15

PROCEDURE

UV light therapy

Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.

Trial Locations (1)

44106

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT00068523 - Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter